vs

Side-by-side financial comparison of Ecovyst Inc. (ECVT) and NEOGENOMICS INC (NEO). Click either name above to swap in a different company.

Ecovyst Inc. is the larger business by last-quarter revenue ($199.4M vs $186.7M, roughly 1.1× NEOGENOMICS INC). On growth, Ecovyst Inc. posted the faster year-over-year revenue change (34.0% vs 11.1%). Over the past eight quarters, Ecovyst Inc.'s revenue compounded faster (18.7% CAGR vs 6.5%).

Ecovyst Inc. is a global sustainable specialty materials provider that develops and manufactures high-performance catalysts and functional additives. Its offerings serve key segments including industrial manufacturing, consumer goods, and environmental protection, helping clients improve operational efficiency and lower carbon emissions across North America, Europe, and Asia-Pacific markets.

NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics.

ECVT vs NEO — Head-to-Head

Bigger by revenue
ECVT
ECVT
1.1× larger
ECVT
$199.4M
$186.7M
NEO
Growing faster (revenue YoY)
ECVT
ECVT
+22.9% gap
ECVT
34.0%
11.1%
NEO
Faster 2-yr revenue CAGR
ECVT
ECVT
Annualised
ECVT
18.7%
6.5%
NEO

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ECVT
ECVT
NEO
NEO
Revenue
$199.4M
$186.7M
Net Profit
$-108.0M
Gross Margin
23.4%
43.3%
Operating Margin
10.9%
46.9%
Net Margin
-57.9%
Revenue YoY
34.0%
11.1%
Net Profit YoY
42.0%
EPS (diluted)
$0.06
$-0.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ECVT
ECVT
NEO
NEO
Q1 26
$186.7M
Q4 25
$199.4M
$190.2M
Q3 25
$204.9M
$187.8M
Q2 25
$176.1M
$181.3M
Q1 25
$143.1M
$168.0M
Q4 24
$148.9M
$172.0M
Q3 24
$153.9M
$167.8M
Q2 24
$154.0M
$164.5M
Net Profit
ECVT
ECVT
NEO
NEO
Q1 26
$-108.0M
Q4 25
Q3 25
$-79.3M
$-27.1M
Q2 25
$6.0M
$-45.1M
Q1 25
$-3.6M
$-25.9M
Q4 24
Q3 24
$14.3M
$-17.7M
Q2 24
$8.3M
$-18.6M
Gross Margin
ECVT
ECVT
NEO
NEO
Q1 26
43.3%
Q4 25
23.4%
43.8%
Q3 25
25.4%
42.8%
Q2 25
22.8%
42.6%
Q1 25
13.3%
43.6%
Q4 24
28.9%
44.9%
Q3 24
29.3%
44.6%
Q2 24
27.3%
44.1%
Operating Margin
ECVT
ECVT
NEO
NEO
Q1 26
46.9%
Q4 25
10.9%
-7.1%
Q3 25
13.8%
-14.4%
Q2 25
9.0%
-26.3%
Q1 25
-0.7%
-16.6%
Q4 24
15.1%
-10.7%
Q3 24
17.9%
-12.6%
Q2 24
14.1%
-13.3%
Net Margin
ECVT
ECVT
NEO
NEO
Q1 26
-57.9%
Q4 25
Q3 25
-38.7%
-14.4%
Q2 25
3.4%
-24.9%
Q1 25
-2.5%
-15.4%
Q4 24
Q3 24
9.3%
-10.5%
Q2 24
5.4%
-11.3%
EPS (diluted)
ECVT
ECVT
NEO
NEO
Q1 26
$-0.13
Q4 25
$0.06
Q3 25
$-0.69
Q2 25
$0.05
Q1 25
$-0.03
Q4 24
$-0.26
Q3 24
$0.12
Q2 24
$0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ECVT
ECVT
NEO
NEO
Cash + ST InvestmentsLiquidity on hand
$197.2M
$146.1M
Total DebtLower is stronger
$392.6M
Stockholders' EquityBook value
$603.4M
$828.8M
Total Assets
$1.3B
$1.3B
Debt / EquityLower = less leverage
0.65×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ECVT
ECVT
NEO
NEO
Q1 26
$146.1M
Q4 25
$197.2M
$159.6M
Q3 25
$82.0M
$164.1M
Q2 25
$69.6M
$154.7M
Q1 25
$127.5M
$346.2M
Q4 24
$131.4M
$367.0M
Q3 24
$123.5M
$362.0M
Q2 24
$83.3M
$355.1M
Total Debt
ECVT
ECVT
NEO
NEO
Q1 26
Q4 25
$392.6M
$341.9M
Q3 25
$854.8M
Q2 25
$856.6M
Q1 25
$859.0M
Q4 24
$860.8M
$541.1M
Q3 24
$862.7M
Q2 24
$862.4M
Stockholders' Equity
ECVT
ECVT
NEO
NEO
Q1 26
$828.8M
Q4 25
$603.4M
$836.6M
Q3 25
$607.9M
$838.3M
Q2 25
$692.4M
$854.0M
Q1 25
$698.7M
$888.3M
Q4 24
$700.5M
$902.3M
Q3 24
$729.4M
$908.2M
Q2 24
$717.3M
$915.9M
Total Assets
ECVT
ECVT
NEO
NEO
Q1 26
$1.3B
Q4 25
$1.3B
$1.4B
Q3 25
$1.7B
$1.4B
Q2 25
$1.8B
$1.4B
Q1 25
$1.8B
$1.6B
Q4 24
$1.8B
$1.6B
Q3 24
$1.8B
$1.6B
Q2 24
$1.8B
$1.6B
Debt / Equity
ECVT
ECVT
NEO
NEO
Q1 26
Q4 25
0.65×
0.41×
Q3 25
1.41×
Q2 25
1.24×
Q1 25
1.23×
Q4 24
1.23×
0.60×
Q3 24
1.18×
Q2 24
1.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ECVT
ECVT
NEO
NEO
Operating Cash FlowLast quarter
$41.8M
$-8.1M
Free Cash FlowOCF − Capex
$22.9M
FCF MarginFCF / Revenue
11.5%
Capex IntensityCapex / Revenue
9.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$69.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ECVT
ECVT
NEO
NEO
Q1 26
$-8.1M
Q4 25
$41.8M
$1.3M
Q3 25
$55.3M
$8.9M
Q2 25
$33.0M
$20.3M
Q1 25
$10.3M
$-25.3M
Q4 24
$43.5M
$9.8M
Q3 24
$59.9M
$9.2M
Q2 24
$10.0M
$13.9M
Free Cash Flow
ECVT
ECVT
NEO
NEO
Q1 26
Q4 25
$22.9M
$-6.5M
Q3 25
$53.2M
$570.0K
Q2 25
$7.8M
$14.0M
Q1 25
$-14.0M
$-29.8M
Q4 24
$30.9M
$-1.8M
Q3 24
$53.6M
$-1.6M
Q2 24
$-9.3M
$814.0K
FCF Margin
ECVT
ECVT
NEO
NEO
Q1 26
Q4 25
11.5%
-3.4%
Q3 25
26.0%
0.3%
Q2 25
4.4%
7.7%
Q1 25
-9.8%
-17.8%
Q4 24
20.7%
-1.0%
Q3 24
34.9%
-0.9%
Q2 24
-6.1%
0.5%
Capex Intensity
ECVT
ECVT
NEO
NEO
Q1 26
Q4 25
9.4%
4.1%
Q3 25
1.0%
4.4%
Q2 25
14.4%
3.5%
Q1 25
16.9%
2.7%
Q4 24
8.5%
6.7%
Q3 24
4.1%
6.4%
Q2 24
12.5%
8.0%
Cash Conversion
ECVT
ECVT
NEO
NEO
Q1 26
Q4 25
Q3 25
Q2 25
5.52×
Q1 25
Q4 24
Q3 24
4.21×
Q2 24
1.20×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ECVT
ECVT

Industrial Mining Automotive$101.3M51%
Regeneration And Treatment Services$90.0M45%
Other$8.1M4%

NEO
NEO

Segment breakdown not available.

Related Comparisons